The novel combination of sirolimus and bortezomib prevents graft-versus-host disease but maintains the graft-versus-leukemia effect after allogeneic transplantation

Haematologica

Volumn 97, Issue 9, 2012, Pages 1329-1337

  Caballero Velázquez, Teresa ^a   Sánchez Abarca, Luis Ignacio ^a   Gutierrez Cosio, Silvia ^a   Blanco, Belén ^b   Calderon, Cristina ^a   Herrero, Carmen ^b   Carrancio, Soraya ^b   Serrano, Concepción ^b   del Cañizo, Consuelo ^b   San Miguel, Jesús F ^b   Pérez Simón, José A ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b CSIC   (Spain)

Author keywords

Allogeneic transplant; Bortezomib; Graft versus host; Graft versusleukemia; Sirolimus

Indexed keywords

BORTEZOMIB; CD4 ANTIGEN; CD40 LIGAND; CYCLOSPORIN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RAPAMYCIN; TUMOR NECROSIS FACTOR; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; CYTOKINE; PYRAZINE DERIVATIVE;

ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD25+ T LYMPHOCYTE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; LEUKEMIA; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; SPLEEN CELL; T LYMPHOCYTE; WESTERN BLOTTING; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL PROLIFERATION; DRUG EFFECTS; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; IMMUNOLOGY; LEUKEMIA, EXPERIMENTAL; METABOLISM; NONOBESE DIABETIC MOUSE; REGULATORY T LYMPHOCYTE; TRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE MARROW TRANSPLANTATION; BORONIC ACIDS; CELL PROLIFERATION; CYTOKINES; FEMALE; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; LEUKEMIA, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; PYRAZINES; SIROLIMUS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84865979985     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.058677     Document Type: Article

References (39)

1. Sorror ML, Leisenring W, Deeg HJ, Martin PJ, Storb R. Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graftversus-host disease in patients administered HLA-identical marrow grafts for leukemia. Biol Blood Marrow Transplant. 2005;11(10):814-5.
2. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96(6):2062-8.
3. Pérez-Simón JA, Encinas C, Silva F, Arcos MJ, Díez-Campelo M, Sánchez-Guijo FM, et al. Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. Biol Blood Marrow Transplant. 2008; 14(10):1163-71.
4. Stewart BL, Storer B, Storek J, Deeg HJ, Storb R, Hansen JA, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood. 2004; 104(12):3501-6.
5. Coenen JJ, Koenen HJM, Van Rijssen E, Hilbrands LB, Joosten I. Rapamycin, and not Cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood. 2006;107(3):1018-23.
6. Segundo DS, Ruiz JC, Izquierdo M, Fernández-Fresnedo G, Gómez-Alamillo C, Merino R, et al. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation. 2006;82(4):550-7.
7. Wang H, Zhao L, Sun Z, Sun L, Zhang B, Zhao Y. A potential side effect of cyclosporin A: inhibition of CD4(+) CD25(+) regulatory T cells in mice. Transplantation. 2006;82(11):1484-92.
8. Coenen JJ, Koenen HJ, van Rijssen E, Kasran A, Boon L, Hilbrands LB, et al. Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4(+)CD25(+)FoxP3(+) T cells. Bone Marrow Transplant. 2007;39(9):537-45.
9. Gao W, Lu Y, El Essawy B, Oukka M, Kuchroo VK, Strom TB. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant. 2007;7(7):1722-32.
10. Noris M, Casiraghi F, Todeschini M, Cravedi P, Cugini D, Monteferrante G, et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol. 2007;18(3):1007-18.
11. Finke J, Behge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, et al. Socié G; ATG-Fresenius Trial Group. ATG fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855-64.
12. Bacigalupo A, Lamparelli T, Milone G, Sormani MP, Ciceri F, Peccatori J, et al. Gruppo Italiano Trapianto Midollo Osseo (GITMO). Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day+7 after alternative donor transplants. Bone Marrow Transplant. 2010;45(2):385-91.
13. Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ, Antin JH. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007;109(7): 3108-14.
14. Récher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood. 2005;105 (6):2527-34.
15. Vaysberg M, Balatoni CE, Nepomuceno RB, Krams SM, Martinez OM. Rapamycin inhibits proliferation of Epstein-Barr viruspositive B-cell lymphomas through modulation of cell-cycle protein expression. Transplantation. 2007;83(8):1114-21.
16. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol. 2006;177(12): 8338-47.
17. Uss E, Yong SL, Hooibrink B, van Lier RA, Ten Berge IJ. Rapamycin enhances the number of alloantigen-induced human CD103+CD8+ regulatory T cells in vitro. Transplantation. 2007;83(8):1098-106.
18. Zeiser R, Leveson-Gower DB, Zambricki EA, Kambham N, Beilhack A, Loh J, Hou JZ, Negrin RS, et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood. 2008;111(1):453-62.
19. Fortin MC, Raymond MA, Madore F, Fugère JA, Pâquet M, St-Louis G, et al. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporinesirolimus combination. Am J Transplant. 2004;4(6):946-52.
20. Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. 2005;5(6):472-84.
21. Blaha P, Bigenzahn S, Koporc Z, Schmid M, Langer F, Selzer E, et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood. 2003;101(7):2886-93.
22. Hideshima T, Richardson P, Chauhan D, Palombella V, Elliot E, Adams J, Anderson K. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61(7): 3071-6
23. Palombella V, Rando O, Goldberg A, Maniatis T. The ubiquitin proteasome pathway is required for processing the NFkB1 precursor protein and the activation of NF-kB. Cell. 1994;78(5):773-85.
24. Li B, Dou Q. Bax degradation by the ubiquitin/proteasome dependent pathway: involvement in tumor survival and progression. Proc Nat Acad Sci USA. 2000;97(8): 3835-55.
25. Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, Carvajal-Vergara X, Mateos J, Vidriales B, et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood. 2006;107(9):3575-83.
26. Koreth J, Stevenson KE, Kim HT, Garcia M, Ho VT, Armand P, Cutler C, et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLAmismatched unrelated donors. Blood. 2009;114(18):3956-9.
27. Blanco B, Perez-Simón JA, Sánchez-Abarca LI, Caballero-Velazquez T, Gutierrez-Cossío S, Hernández-Campo P, et al. Treatment with bortezomib of human CD4+ T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population. Haematol-ogica. 2009;94(7):975-83.
28. Cooke KR, Kobzik L, Martín TR, Brewer J, Delmonte J Jr, Crawford JM, et al. An Experimental Model of Idiopathic Pneumonia Syndrome After Bone Marrow Transplantation: I. The Roless of Minor H Antigens and Endotoxin. Blood. 1996;88(8): 3230-9
29. Deeg HJ, Storb R, Weiden PL, Raff RF, Sale GE, Atkinson K, et al. Cyclosporin A and methotrexate in canine marrow transplantation: engraftment, graft-versus-host disease, and induction of intolerance. Transplantation. 1982;34(1):30-5.
30. Storb R, Kolb HJ, Deeg HJ, Weiden PL, Appelbaum F, Graham TC, et al. Prevention of graft-versus-host disease by immunosuppressive agents after transplantation of DLA-nonidentical canine marrow. Bone Marrow Transplant. 1986;1(2):167-77.
31. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis for leukemia. N Engl J Med. 1986;314(12):729-35.
32. Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P, et al. Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood. 1986;68(1):119-25.
33. Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008;112(12): 4425-31.
34. Rodriguez R, Nakamura R, Palmer JM, Parker P, Shayani S, Nademanee A, et al. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens. Blood. 2010;115(21):1098-105.
35. Vogelbacher R, Meister S, Gückel E, Starke C, Wittmann S, Stief A, et al. Bortezomib and sirolimus inhibit the chronic active antibody-mediated rejection in experimental renal transplantation in the rat. Nephrol Dial Transplant. 2010;25(11):3764-73.
36. Kim JS, Lee JI, Shin JY, Kim SY, Shin JS, Lim JH, et al. Bortezomib can suppress activation of rapamycin-resistant memory T cells without affecting regulatory T-cell viability in non-human primates. Transplantation. 2009;27;88(12):1349-59.
37. Lundqvist A, Abrams SI, Schrump DS, Alvarez G, Suffredini D, Berg M, Childs R. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 2006;66(14):7317-25.
38. Lundqvist A, Yokoyama H, Smith A, Berg M, Childs R. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood. 2009;113(24):6120-7.
39. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther. 2005;4(10):1533-40.